Drugs used to treat and prevent diabetic kidney disease

A technology for diabetic nephropathy and a drug, applied in the field of diabetic nephropathy, can solve the problems of undiscovered combination treatment of diabetic nephropathy with Tagagliflozin and DPP-4 inhibitor, and achieve the effects of improving compliance, stable drug effect and good curative effect.

Active Publication Date: 2021-06-22
GUANGZHOU LIXIN PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] So far, no patent literature has been found on the combination of tepagliflozin and DPP-4 inhibitors in the treatment of diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drugs used to treat and prevent diabetic kidney disease
  • Drugs used to treat and prevent diabetic kidney disease
  • Drugs used to treat and prevent diabetic kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1, compound medicine tablet of the present invention

[0025] Recipe: (1000 tablets)

[0026] Tegliflozin 10g

[0027] Vildagliptin 10g

[0028] Microcrystalline Cellulose 16.2g

[0029] β-cyclodextrin 19.4g

[0030] L-fucose 24.4g

[0031] 5% povidone 95% ethanol solution appropriate amount

[0032] Magnesium Stearate 1.0%

[0033] Preparation method: take the prescribed amount of tepagliflozin and vildagliptin and mix them uniformly according to the method of equal increase, set aside, weigh the prescribed amount of microcrystalline cellulose, β-cyclodextrin and L-fucose, and mix with the raw materials The drug is fully mixed, passed through a 80-mesh sieve, and an appropriate amount of 5% povidone 95% ethanol solution is added to make a soft material, granulated with a 25-mesh sieve, dried at 50°C for 6 hours, and granulated with a 25-mesh granule, and the water content of the granules is controlled to be 2- 3%, the dried granules are mixed evenly w...

Embodiment 2

[0034] Embodiment 2, compound medicine tablet of the present invention

[0035] Recipe: (1000 tablets)

[0036] Tegliflozin 50g

[0037] Saxagliptin 20g

[0038] Microcrystalline Cellulose 85.4g

[0039] β-cyclodextrin 110.9g

[0040] L-fucose 153.7g

[0041] 5% povidone 95% ethanol solution appropriate amount

[0042] Magnesium Stearate 1.0%

[0043] The preparation method was the same as in Example 1, and each tablet of the prepared compound drug contained 50 mg of tipagliflozin and 20 mg of saxagliptin.

Embodiment 3

[0044] Embodiment 3, compound medicine tablet of the present invention

[0045] Recipe: (1000 tablets)

[0046] Tegliflozin 75g

[0047] Vildagliptin 30g

[0048] Microcrystalline Cellulose 133.3g

[0049] β-cyclodextrin 200g

[0050] L-fucose 266.7g

[0051] 5% povidone 95% ethanol solution appropriate amount

[0052] Magnesium Stearate 1.0%

[0053] The preparation method was the same as in Example 1, and each tablet of the prepared compound drug contained 75 mg of tipagliflozin and 30 mg of vildagliptin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the technical field of diabetic nephropathy, in particular to a drug for treating and preventing diabetic nephropathy, which includes tepagliflozin and DPP-4 inhibitors, the content of tepagliflozin is 10-100 mg, The content of the DPP-4 inhibitor is 10-50mg. The medicine prepared by the present invention can significantly reduce the content or expression of blood urea nitrogen, blood creatinine, 24h urine protein, urine protein quantification and transforming growth factor-β1, significantly improve the expression of Clotho protein, and treat and prevent diabetic nephropathy The effect is better, it can be stored for a long time, and the toxic and side effects are small.

Description

technical field [0001] The invention relates to the technical field of diabetic nephropathy, in particular to a medicine for treating and preventing diabetic nephropathy. Background technique [0002] Diabetes and its chronic complications have seriously affected human health and quality of life. In recent years, the number of people with diabetes has been on the rise. The incidence of diabetes in all age groups in the world was about 2.8% in 2000 and is expected to be 4.4% by 2030. Diabetic nephropathy is one of the most important comorbidities in diabetic patients. The incidence rate in my country is also on the rise, and it has become the second cause of end-stage renal disease, second only to various glomerulonephritis. Due to its complex metabolic disorders, once it develops into end-stage renal disease, it is often more difficult to treat than other kidney diseases. Therefore, timely prevention and treatment is of great significance for delaying diabetic nephropathy. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/351A61K45/06A61P13/12A61P3/10A61K9/48A61K9/20
CPCA61K9/2054A61K9/4866A61K31/351A61K45/06A61P3/10A61P13/12
Inventor 高悦译赵桂龙陈成斌蒋莉娟刘恩桂王灿顶韩锋赖文燕黄夏梦
Owner GUANGZHOU LIXIN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap